Tocqueville Asset Management LP Boosts Position in Clovis Oncology, Inc. (CLVS)

Marco Green
November 15, 2017

Jennison Associates LLC now owns 1,185,177 shares of the biopharmaceutical company's stock worth $110,968,000 after purchasing an additional 817,677 shares during the last quarter. The most current P/E ratio is N/A and the market cap of the company is 3.28B. The stock declined 0.79% or $0.52 reaching $65.47 on the news. It also upped Audentes Therapeutics Inc stake by 638,780 shares and now owns 1.46 million shares. The original version of this piece can be read at It has outperformed by 266.01% the S&P500.

Walthausen & Company, which manages about $1.45 billion and $1.02 billion US Long portfolio, decreased its stake in Unifi Inc (NYSE:UFI) by 42,728 shares to 417,226 shares, valued at $12.85 million in 2017Q2, according to the filing. Walthausen & Company who had been investing in Dst Systems Inc for a number of months, seems to be bullish on the $3.60 billion market cap company. (CLVS)'s stock declined 20.61%. About 474,583 shares traded. PulteGroup, Inc. (NYSE:PHM) has risen 30.02% since November 14, 2016 and is uptrending. It has outperformed by 6.81% the S&P500.

On November 3 Stifel Nicolaus left the company rating at "Buy" projecting a price of $125.00. Therefore 70% are positive. Credit Suisse upgraded the stock to "Outperform" rating in Wednesday, September 21 report. Finally, BidaskClub downgraded Clovis Oncology from a "strong-buy" rating to a "buy" rating in a report on Wednesday, August 9th. Stifel Nicolaus maintained the stock with "Buy" rating in Wednesday, September 21 report. The stock has "Buy" rating by Stifel Nicolaus on Friday, February 26. The company was maintained on Friday, September 23 by Suntrust Robinson. On Friday, August 5 the stock rating was initiated by Suntrust Robinson with "Buy". Chardan Capital Markets has "Neutral" rating and $36 target. The rating was downgraded by JP Morgan on Wednesday, April 13 to "Neutral". Its position was valued at $2,472,000 an increase of 32.0% according to the filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company.

Clovis Oncology (NASDAQ:CLVS) opened at 40.48 on Monday. University Of Notre Dame Du Lac has invested 1.41% in Clovis Oncology Inc (NASDAQ:CLVS).

Investors sentiment decreased to 1.81 in Q2 2017. Its down 0.66, from 2.47 in 2017Q1. Nationwide Fund Advisors raised its stake in Clovis Oncology by 15.4% in the second quarter. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.19 and a quick ratio of 3.16. Lpl Financial Ltd Liability reported 0% stake. Tekla Capital Management LLC now holds 75,400 shares worth $6,213,000. Teacher Retirement Sys Of Texas reported 3,211 shares stake. (CLVS) stake by 27.08% reported in 2017Q2 SEC filing. 1,115 were accumulated by Focused Wealth. Clovis Oncology earned a daily sentiment score of 0.13 on Accern's scale. Immunogen Inc (NASDAQ:IMGN) was raised too. Raymond James &, Florida-based fund reported 7,581 shares. Oppenheimer Holdings, Inc. reissued a "hold" rating on shares of Clovis Oncology in a research note on Monday, September 11th.

Clovis Oncology, Inc., launched on April 20, 2009, is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other global markets.

Since May 15, 2017, it had 0 insider buys, and 1 sale for $185,460 activity. (NYSE:PHM) were recently published by:, which released: "PulteGroup, Inc". (NYSE:DST) was released by: and their article: "DST Systems (DST) Q3 Earnings & Revenues Beat Estimates" with publication date: October 23, 2017.'s article titled: "The Detroit Free Press Names Pultegroup's Michigan Division a victor of the ..." and published on November 07, 2017 is yet another important article. Eight analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Therefore 50% are positive. Safe Bulkers had 20 analyst reports since October 23, 2015 according to SRatingsIntel. (NYSE:PHM) on Thursday, July 13 to "Neutral" rating. The firm earned "Buy" rating on Friday, January 27 by Bank of America.

Barclays PLC released research on CLVS giving it an initial rating of "Overweight". They issued a "sector perform" rating and a $81.00 target price for the company. As per Thursday, September 29, the company rating was initiated by Wells Fargo.

Since May 16, 2017, it had 1 buy, and 1 sale for $1.19 million activity. Manufacturers Life The invested in 0% or 30,408 shares. It dropped, as 35 investors sold PHM shares while 170 reduced holdings. The biopharmaceutical company reported ($1.24) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.18) by ($0.06). Amica Pension Fund Board Of Trustees has invested 0.05% in PulteGroup, Inc. Boothbay Fund Limited Liability holds 0.05% or 2,567 shares in its portfolio. Kbc Nv accumulated 54,089 shares. Koch Industries invested in 228,800 shares. Redmile Grp Incorporated reported 764,389 shares. Phocas Fincl Corp holds 1,200 shares. Carroll Financial Assocs has invested 0% in PulteGroup, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by Click Lancashire

Discuss This Article